A Randomised, cross-over study to compare the safety, tolerability and pharmacokinetics of inhaled PA101 (Patara Pharma) to currently used formulations (Nalcrom® oral solution, and IntalTM nebulizer solution) in healthy volunteers, indolent systemic mastocytosis (ISM) and allergic asthma patients

Trial Profile

A Randomised, cross-over study to compare the safety, tolerability and pharmacokinetics of inhaled PA101 (Patara Pharma) to currently used formulations (Nalcrom® oral solution, and IntalTM nebulizer solution) in healthy volunteers, indolent systemic mastocytosis (ISM) and allergic asthma patients

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Sodium cromoglicate (Primary) ; Sodium cromoglicate
  • Indications Allergic asthma; Systemic mastocytosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Jul 2017 New trial record
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top